Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
Merck gets FDA nod for new antibiotic, but says use with careThe FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have Share XMerck gets FDA nod for new antibiotic, but says use with carehttps://pharmaphorum.com/news/merck-gets-fda-nod-for-new-antibiotic-but-says-use-with-care/
J&J warns generics will bite its pharma unit in the second halfJohnson & Johnson has kicked off the interim results season with a warning that low-cost generic and biosimilar Share XJ&J warns generics will bite its pharma unit in the second halfhttps://pharmaphorum.com/news/jj-warns-generics-will-bite-its-pharma-unit-in-the-second-half/
NICE changes its mind on Novartis’ Kisqali for breast cancerNICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England Share XNICE changes its mind on Novartis’ Kisqali for breast cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-kisqali-for-breast-cancer/
All eyes on Oklahoma as J&J awaits $17bn opioid case verdictThe multibillion dollar opioid liability lawsuit filed by the state of Oklahoma against Johnson & Johnson came to Share XAll eyes on Oklahoma as J&J awaits $17bn opioid case verdicthttps://pharmaphorum.com/news/all-eyes-on-oklahoma-as-jj-awaits-17bn-opioid-case-verdict/
GSK eyeing industry vet Jonathan Symonds as new chair; reportGlaxoSmithKline is reported to have found the person it wants to replace Sir Philip Hampton as its non-executive Share XGSK eyeing industry vet Jonathan Symonds as new chair; reporthttps://pharmaphorum.com/news/gsk-eyeing-industry-vet-jonathan-symonds-as-new-chair-report/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
